IL165516A0 - Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues - Google Patents

Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues

Info

Publication number
IL165516A0
IL165516A0 IL16551602A IL16551602A IL165516A0 IL 165516 A0 IL165516 A0 IL 165516A0 IL 16551602 A IL16551602 A IL 16551602A IL 16551602 A IL16551602 A IL 16551602A IL 165516 A0 IL165516 A0 IL 165516A0
Authority
IL
Israel
Prior art keywords
drug substance
toluidine blue
chemotherapeutic treatment
vivo staining
dysplastic tissues
Prior art date
Application number
IL16551602A
Original Assignee
Zila Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zila Inc filed Critical Zila Inc
Publication of IL165516A0 publication Critical patent/IL165516A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B21/00—Thiazine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL16551602A 2002-06-04 2002-06-04 Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues IL165516A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/017720 WO2003103569A2 (en) 2002-06-04 2002-06-04 Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues

Publications (1)

Publication Number Publication Date
IL165516A0 true IL165516A0 (en) 2006-01-15

Family

ID=29731309

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16551602A IL165516A0 (en) 2002-06-04 2002-06-04 Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues

Country Status (9)

Country Link
EP (1) EP1534346A4 (en)
JP (1) JP2005535605A (en)
CN (1) CN1302815C (en)
AU (1) AU2002312319A1 (en)
BR (1) BRPI0215775A2 (en)
IL (1) IL165516A0 (en)
MX (1) MXPA04012031A (en)
TW (1) TW200733956A (en)
WO (1) WO2003103569A2 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH071257B2 (en) * 1985-09-09 1995-01-11 エスエス製薬株式会社 Simultaneous determination of water-soluble vitamins in mixed vitamin preparations
JPS6410171A (en) * 1987-07-03 1989-01-13 Shimadzu Corp Analysis of amino acid
DK0565668T3 (en) * 1991-10-31 2000-01-31 Zila Inc Biological dye composition, method of preparation thereof and for use in epithelial cancer signaling
AU5357498A (en) * 1997-11-13 1999-06-07 Zila, Inc. (in vivo) stain composition, process of manufacture, and methods of use to identify dysplastic tissue
US6194573B1 (en) * 1997-11-13 2001-02-27 Zila, Inc. Process for manufacture of in vivo stain composition
US6086852A (en) * 1997-11-13 2000-07-11 Zila, Inc. In vivo stain composition, process of manufacture, and methods of use to identify dysplastic tissue
AU2000237154A1 (en) * 2000-02-28 2001-09-12 Zila, Inc. Method for detecting and killing epithelial cancer cells
JP4424838B2 (en) * 2000-08-31 2010-03-03 株式会社トクヤマ Analysis method for quaternary ammonium salts

Also Published As

Publication number Publication date
TW200733956A (en) 2007-09-16
EP1534346A2 (en) 2005-06-01
JP2005535605A (en) 2005-11-24
CN1627961A (en) 2005-06-15
WO2003103569A3 (en) 2004-05-21
BRPI0215775A2 (en) 2016-07-05
CN1302815C (en) 2007-03-07
MXPA04012031A (en) 2005-03-07
AU2002312319A1 (en) 2003-12-22
WO2003103569A2 (en) 2003-12-18
EP1534346A4 (en) 2007-07-25

Similar Documents

Publication Publication Date Title
AU2002347575A1 (en) Dosing and administration of therapeutic micro-organs in living subjects and devices and methods for same
HUP0500498A3 (en) A nutrient pharmaceutical formulation comprising polyphenols for use in treatment of cancer
EP1675570A4 (en) Use of photodynamic therapeutic agents entrapped in ceramic nanoparticles
AU2003239531A8 (en) Protein cages for the delivery of medical imaging and therapy
HK1070080A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the preparation of medicament for the diagnosis and treatment of tumors
IL180434A0 (en) Human glucagon - like - peptide - 1 modulators and their use in the treatment of diabetes and related conditions
HK1162948A1 (en) Hemiasterlin derivatives and uses thereof in the treatment of cancer (hemiasterlin)
HUP0700151A2 (en) Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
EP1551990A4 (en) Diagnosis and treatment of chemoresistant tumors
EP1594476A4 (en) Method and apparatus for treating bodily tissues with medicinal substance
HUP0400918A3 (en) Utilization of pyrazoline derivatives in the preparation of pharmaceutical compositions for the prevention and/or treatment of proliferative cell diseases
HUP0302726A3 (en) Methods of administering pharmaceutical composition containing epothilone analogs for the treatment of cancer and of preparation the same
EP1385465A4 (en) Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
PL369521A1 (en) Heterocyclic derivatives of glycinamide and their medical use
IL172704A (en) Pharmaceutical composition comprising a salinosporamide compound and use thereof in the manufacture of a medicament for treating cancer
ZA200610786B (en) Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
IS6967A (en) New cyano-linked dihydropyrimidine compounds and their use in the treatment of diseases
DE60107034D1 (en) Mixing and loading opening for medical treatment
EP1491210A4 (en) Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles
IL165516A0 (en) Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues
IL162941A0 (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
EP1591450A4 (en) Conjugate for retention in blood and cancer tissue-specific drug delivery
EP1182929A4 (en) Osteonectin based toxic gene therapy for the treatment of calcified tumors and tissues
IL166588A0 (en) Containing disorazoles and derivatives thereof forthe treatment of benign and malignant tumoral dis eases
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases